{"prompt": "['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 64 of 74', '23.6 Appendix 6 Sample size ouput and predictive power', 'Sample size for a planned phase III trial: sample size N=~1000, number of PFS events', 'm=846', 'Sample size with a 5% significance level and 90% power for a hazard ratio = 0.80, a median PFS of', '12 months, a 4-year recruitment, a 2-year follow up.', 'artsurv, method(I inperiod(6) Ingroups(2) fp(0) median(1) hratio(1, 0.8, 0.8) alpha(0.05)', 'power(0.9) aratios(1 1 ) recrt(4 0, 1, 0 ) distant(0) detail(0) onesid ed(0) ni(0) tunit(1)', 'trend(0)', 'ART - ANALYSIS OF RESOURCES FOR TRIALS', '(version 1.0.7, 19 October 2009)', 'A sample size program by Abdel Babiker, Patrick Royston & Friederike Barthel,', 'MRC Clinical Trials Unit, London NW1 2DA, UK.', 'Type of trial', 'Superiority - time-to-event outcome', 'Statistical test assumed', 'Unweighted logrank test (local)', 'Number of groups', '2', 'Allocation ratio', 'Equal group sizes', 'Total number of periods', '6', 'Length of each period', 'One year', 'Baseline median survival time', '1 year', 'Survival probs per period (group 1)', '0.500 0.250 0.125 0.063 0.031 0.016', 'Survival probs per period (group 2)', '0.574 0.330 0.189 0.1090.0630.036', 'Number of recruitment periods', '4', 'Number of follow-up periods', '2', 'Method of accrual', 'Uniform', 'Recruitment period-weights', '1 1 1 1 0 0', 'Hazard ratios as entered (groups 1,2)', '1, 0.8', 'Alpha', '0.050 (two-sided)', 'Power (designed)', '0.900', 'Total sample size (calculated)', '949', 'Expected total number of events', '846', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']['EudraCT number: 2016-005228-27', 'IRAS ID Number: 213113', 'Page 65 of 74', 'Predictive power for a successful phase III trial', 'prior,=log(HR)~N(0,0), =', 'data Xn I u N (11.) n = total no. of PFS events observed in the fesiblity study', 'p =', 'predictive likelihood XmlXn ~ N m = totalno. of PFS events', 'The preditive power PP(m) to reject Ho ( hazard ratio (HR) 1, or log (HR) 0 (T=0)) of no PFS benefit', 'of intermittent dosing schedul is', '8', 'PP(m) = Q', 'With a prior of no difference and 1 PFS event, that is log(HR) ~ N(0, 4), significance level a = 5%, n=90', 'PFS events observed in the feasiblity study,', 'if the observed HR=0.80 (an improvement in median PFS from 12 to 15 months) in the phase Il', 'trial, the predictive power to reject the null hypothesis of no PFS benefit of intermittent dosing', 'schedule under the planned phase III trial (m=846) is 72%.', 'If the observed HR=0.75 (an improvement in median PFS from 12 to 16 months) in the phase Il', 'trial, the predictive power to reject the null hypothesis of no PFS benefit of intermittent dosing', 'schedule under the planned phase III trial (m=846) is 81%.', 'INTERIM', 'Protocol Version: V1.1 Version Date: 21 September 2017']\n\n###\n\n", "completion": "END"}